Latest News
View AllApr 07, 2021
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference
Read MoreMar 15, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read MoreMar 09, 2021
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
Read MoreMar 03, 2021
Gamida Cell to Present at Upcoming Investor Conferences
Read MoreMar 02, 2021
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast
Read MoreMar 01, 2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read MoreFeb 16, 2021
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
Read MoreFeb 09, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
Read MoreJan 11, 2021
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Read MoreJan 05, 2021
Gamida Cell to Present at Upcoming January Investor Conferences
Read MoreDec 21, 2020
Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read MoreDec 18, 2020
Gamida Cell Added to NASDAQ Biotechnology Index
Read MoreDec 17, 2020
Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares
Read MoreDec 16, 2020
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
Read MoreDec 14, 2020
Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
Read MoreDec 09, 2020
Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020
Read MoreDec 05, 2020
Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition
Read MoreDec 02, 2020
Gamida Cell to Host Virtual Pipeline Deep Dive
Read MoreNov 24, 2020
Gamida Cell to Present at Upcoming Conferences
Read MoreNov 10, 2020
Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update
Read MoreNov 04, 2020
Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting
Read MoreNov 04, 2020
Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference
Read MoreNov 02, 2020
Gamida Cell Announces the Date of Its Third Quarter 2020 Financial Results and Webcast
Read MoreOct 13, 2020
Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration
Read MoreOct 07, 2020
Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
Read MoreOct 06, 2020
Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
Read MoreSep 10, 2020
Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting
Read MoreSep 08, 2020
Gamida Cell to Participate in Upcoming Investor Conferences
Read MoreSep 03, 2020
Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September
Read MoreAug 17, 2020
Gamida Cell to Provide Webcast of Its Annual Meeting of Stockholders
Read MoreAug 11, 2020
Gamida Cell Reports Second Quarter 2020 Financial Results and Provides Company Update
Read MoreAug 04, 2020
Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast
Read MoreJul 21, 2020
Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer
Read MoreJul 07, 2020
Gamida Cell Announces Appointment of David Fox to Its Board of Directors
Read MoreJun 12, 2020
Gamida Cell to Present at the JMP Securities Virtual Hematology and Oncology Forum
Read MoreMay 26, 2020
Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read MoreMay 21, 2020
Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update
Read MoreMay 18, 2020
Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary Shares
Read MoreMay 18, 2020
Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares
Read MoreMay 18, 2020
Gamida Cell Announces the Date of Its First Quarter 2020 Financial Results and Webcast
Read MoreMay 12, 2020
Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies
Read MoreMar 02, 2020
Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Read MoreFeb 25, 2020
Gamida Cell Reports Full Year 2019 Financial Results and Provides Company Update
Read MoreFeb 19, 2020
Gamida Cell Announces the Date of Its Full Year 2019 Financial Results and Webcast
Read MoreJan 13, 2020
Gamida Cell Announces 2020 Goals and Provides Company Update
Read MoreJan 02, 2020
Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
Read MoreDec 09, 2019
Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting
Read MoreNov 21, 2019
Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference
Read MoreNov 13, 2019
Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update
Read MoreNov 06, 2019
Gamida Cell Announces Data to be Presented at ASH 2019 Annual Meeting
Read MoreNov 05, 2019
Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and Webcast
Read MoreSep 11, 2019
Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy
Read MoreAug 06, 2019
Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update
Read MoreJul 23, 2019
Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and Webcast
Read MoreJul 08, 2019
Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read MoreJun 26, 2019
Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares
Read MoreJun 24, 2019
Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares
Read MoreJun 19, 2019
Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel
Read MoreJun 05, 2019
Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer
Read MoreMay 31, 2019
Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting
Read MoreMay 29, 2019
Gamida Cell to Hold Annual Meeting of Stockholders
Read MoreMay 09, 2019
Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City
Read MoreMay 07, 2019
Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update
Read MoreApr 30, 2019
Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast
Read MoreApr 22, 2019
Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
Read MoreApr 05, 2019
Gamida Cell to Present at the 18th Annual Needham Healthcare Conference
Read MoreMar 21, 2019
Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
Read MoreFeb 25, 2019
Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Read MoreFeb 23, 2019
Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
Read MoreFeb 21, 2019
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Read MoreFeb 19, 2019
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Read MoreFeb 14, 2019
Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
Read MoreJan 24, 2019
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
Read MoreJan 22, 2019
Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
Read MoreJan 07, 2019
Gamida Cell Announces 2019 Goals and Provides Company Update
Read MoreDec 04, 2018
Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
Read MoreDec 03, 2018
Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting
Read MoreNov 28, 2018
Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Read MoreNov 01, 2018
Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
Read MoreOct 26, 2018
Gamida Cell Announces Pricing of Initial Public Offering
Read MoreSep 18, 2018
Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman
Read MoreAug 06, 2018
Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications
Read MoreJul 23, 2018
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Read MoreJul 17, 2018
Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation
Read MoreJun 18, 2018
Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
Read MoreApr 30, 2018
Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting
Read MoreApr 26, 2018
Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing
Read MoreMar 19, 2018
Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting
Read MoreMar 16, 2018
Gamida Cell to Present at Upcoming Investor Conferences
Read MoreMar 15, 2018
Gamida Cell Appoints Shai Lankry as Chief Financial Officer
Read MoreFeb 20, 2018
Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings
Read MoreJan 16, 2018
Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
Read MoreDec 11, 2017
Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting
Read MoreNov 20, 2017
Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer
Read MoreNov 01, 2017
Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting
Read MoreSep 26, 2017
Gamida Cell World Cord Blood Day Conference, November 15, 2017
Read MoreAug 21, 2017
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
Read MoreJul 10, 2017
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Read MoreJun 19, 2017
Gamida Cell Announces $40 Million Private Financing
Read MoreJun 05, 2017
Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors
Read More@GAMIDACELLTX
April 14, 2021
We are growing our global team of passionate people who are eager to work on improving treatment options for patients with #bloodcancers and serious #blooddiseases. Learn more here: https://t.co/u9IynY8YXE https://t.co/5WxwLcwCw3
April 10, 2021
We are excited to join the AACR Annual Meeting this week which will cover the latest discoveries in cancer research, clinical studies, advocacy and highlights the work of the best minds in research and medicine from institutions all over the world. #AACR2021 https://t.co/Q363TYRA3h
April 7, 2021
We celebrate #WorldHealthDay every year, but this year it takes on many meanings. We recognize the incredible achievements toward improving world health through the prevention and treatment of many diseases, and we are committed to being a part of continued innovation. https://t.co/UPLLSxU7dt
Patient focus
The needs and experiences of patients are at the core of everything we do. Read about one woman’s personal journey through cancer diagnosis and treatment.
Mission-driven science
We are developing a pipeline of potentially curative cell therapies, with our lead program in late-stage development.
Dedicated team
We combine deep scientific experience with a passion for changing the lives of patients.
